

Supplementary information

Time-resolved phenotypic profiling maps EGFR and c-Met trafficking signatures

Kenji Tanabe^{1,*}

¹ Institute for Comprehensive Medical Sciences, Tokyo Women's Medical University,
8-1, Kawada-cho, Shinjuku-ku, 162-8666 Tokyo, Japan

* Correspondence: tanabe.kenji@twmu.ac.jp

Index

Supplementary Figures

Supplementary Figure S1. Representative images of the EGF/EGFR time-course assay.

Supplementary Figure S2. Global overview of compound clustering in the EGF/EGFR time-course assay.

Supplementary Figure S3. EGFR inhibitors define a coherent phenotype in the EGFR time-course assay.

Supplementary Figure S4. Signed (non-aggregated) heatmaps for the EGFR-inhibitor and PI3K-inhibitor clusters.

Supplementary Figure S5. Significance maps corresponding to Fig. 3e.

Supplementary Figure S6. Workflow for the HGF/c-Met time-course assay.

Supplementary Figure S7. Representative images of the HGF/c-Met time-course assay.

Supplementary Figure S8. Global overview of compound clustering in the HGF/c-Met time-course assay.

Supplementary Figure S9. Significance maps corresponding to Fig. 4e.

Supplementary Figure S10. Per-compound granularity rank trajectories and corresponding significance maps for receptor degradation-inhibitor groups.

Supplementary Figure S11. Lipid-marker signatures in receptor degradation-inhibitor groups.

Supplementary Figure S12. Robustness of Fig. 5c signatures to selection-stringency thresholds.

Supplementary Figure S13. Lipid-feature gradients on the fused UMAP and locations of receptor degradation inhibitors.

Supplementary Tables (* provided as a separate CSV file)

Supplementary Table S1. Compound list and plate layout.*

Supplementary Table S2. Compounds excluded by image-based QC.

Supplementary Table S3A. Image feature classes used in EGFR HCS profiling (summary).

Supplementary Table S3B. Complete list of image feature names used in the EGF/EGFR assay analyses.*

Supplementary Table S4A. Image feature classes used in Cell Painting profiling (summary).

Supplementary Table S4B. Complete list of Cell Painting image feature names used in the analyses.*

Supplementary Table S5. Features removed by correlation-based pruning in the EGF/EGFR assay ($|r| \geq 0.95$).*

Supplementary Table S6. Features removed by correlation-based pruning in the Cell Painting dataset ($|r| \geq 0.95$).*

Supplementary Table S7. Duplicate compounds and their plate positions.

Supplementary Table S8. MOA labels used for compound-level classification.*

Supplementary Table S9. Compounds selected as extreme responders for Fig. 3e.

Supplementary Table S10. Representative signed-EMD features used for heatmaps in Figs. 3e, 4e, and 5c.

Supplementary Table S11. Compounds selected as extreme responders for Fig. 4e.

Supplementary Table S12. Empirically defined EGFR and c-Met degradation-inhibitor groups and excluded high-basal compounds (Fig. 5).

Supplementary Table S13. Rationale for assigning degradation-inhibiting compounds to candidate cellular process nodes (Fig. 6c).

Supplementary Table S14A. Image feature classes used in the HGF/c-Met assay (summary).

Supplementary Table S14B. Complete list of image feature names used in the HGF/c-Met assay analyses.*

Supplementary Table S15. Features removed by correlation-based pruning in the HGF/c-Met assay ($|r| \geq 0.95$).*

Supplementary Table S16. Microscope acquisition settings for the EGF and HGF/c-Met time-course assays and the Cell Painting assay.

Supplementary Table S17. Compound list for the hierarchical clustering heatmap in Supplementary Fig. S2 (EGF/EGFR assay).*

Supplementary Table S18. Compound list for the hierarchical clustering heatmap in Supplementary Fig. S8 (HGF/c-Met assay).*